GRAIL's NHS-Galleri Trial Shows Mixed Results: Stage IV Reductions but Misses Primary Endpoint

What happened

GRAIL presented full results from the NHS-Galleri trial at ASCO 2026, revealing that while the annual Galleri blood test did not reduce the combined primary endpoint of Stage III/IV cancers in aggregate, it did reduce Stage IV diagnoses of 12 prespecified cancers by 22% and 26% in the second and third screening rounds, respectively. The test increased cancer detection rate by four-fold when added to standard of care and reduced cancer diagnosis through emergency presentation by 25%. Additionally, annual testing with Galleri increased Stage I-II cancer diagnoses by 16% when added to standard of care. These results provide evidence of clinical utility in downstaging and early detection, but the failure to meet the composite primary endpoint may temper expectations for broad adoption and reimbursement decisions. The data will be critical for GRAIL's PMA submission and ongoing payer discussions, though the mixed top-line outcome introduces uncertainty around the magnitude of benefit.

Implication

The data shows clear benefit in reducing late-stage diagnoses and increasing early detection for prespecified cancers, which could still support PMA and coverage if regulators focus on Stage IV reduction and detection rates. However, the miss on the aggregate Stage III/IV endpoint may require additional evidence or delay regulatory and payer decisions into 2027. Investors should monitor FDA and CMS reactions, particularly whether the Stage IV reduction outweighs the composite miss.

Thesis delta

The NHS-Galleri results are directionally positive for GRAIL's clinical utility argument, but the missed primary endpoint introduces a new risk to the PMA timeline and breadth of label. The prior thesis focused on PMA and reimbursement as binary catalysts; the mixed data may shift the probability of approval and coverage downward slightly, but the data still supports Galleri's value. We see the stock as a HOLD with increased near-term volatility pending regulatory clarity.